Amid a steady stream of new
medications, diagnostics and medical
devices, global policy conversations
about the value of health technology are
more important than ever.
Individual countries vary in their approach
to health technology assessment. But
one factor remains critical: patient
engagement. No country or organisation
can fully capture the value of new
medications or medical devices without
considering the end users.
Patient input allows assessments to
incorporate the lived experiences of
people with the disease treated by the
medication or device being evaluated.
It allows patient advocates to advise
health technology organisations about
the symptoms that most impact quality of
life. Patients? experiences can also guide
health technology organisations in judging
the effectiveness of new treatments using
factors that matter to patients.